420 related articles for article (PubMed ID: 29702672)
1. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
[TBL] [Abstract][Full Text] [Related]
2. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
[TBL] [Abstract][Full Text] [Related]
4. IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.
Karasavvas N; Karnasuta C; Savadsuk H; Madnote S; Inthawong D; Chantakulkij S; Rittiroongrad S; Nitayaphan S; Pitisuttithum P; Thongcharoen P; Siriyanon V; Andrews CA; Barnett SW; Tartaglia J; Sinangil F; Francis DP; Robb ML; Michael NL; Ngauy V; de Souza MS; Paris RM; Excler JL; Kim JH; O'Connell RJ;
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1178-86. PubMed ID: 26234467
[TBL] [Abstract][Full Text] [Related]
5. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
[TBL] [Abstract][Full Text] [Related]
7. Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
Gilbert PB; Excler JL; Tomaras GD; Carpp LN; Haynes BF; Liao HX; Montefiori DC; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Kijak GH; Tovanabutra S; Francis DP; Lee C; Sinangil F; Berman PW; Premsri N; Kunasol P; O'Connell RJ; Michael NL; Robb ML; Morrow R; Corey L; Kim JH
PLoS One; 2017; 12(5):e0176428. PubMed ID: 28493891
[TBL] [Abstract][Full Text] [Related]
8. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
9. Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.
Luo K; Liao HX; Zhang R; Easterhoff D; Wiehe K; Gurley TC; Armand LC; Allen AA; Von Holle TA; Marshall DJ; Whitesides JF; Pritchett J; Foulger A; Hernandez G; Parks R; Lloyd KE; Stolarchuk C; Sawant S; Peel J; Yates NL; Dunford E; Arora S; Wang A; Bowman CM; Sutherland LL; Scearce RM; Xia SM; Bonsignori M; Pollara J; Edwards RW; Santra S; Letvin NL; Tartaglia J; Francis D; Sinangil F; Lee C; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Michael NL; Kim JH; Alam SM; Vandergrift NA; Ferrari G; Montefiori DC; Tomaras GD; Haynes BF; Moody MA
JCI Insight; 2016 Dec; 1(20):e88522. PubMed ID: 27942585
[TBL] [Abstract][Full Text] [Related]
10. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
Williams LD; Shen X; Sawant SS; Akapirat S; Dahora LC; Tay MZ; Stanfield-Oakley S; Wills S; Goodman D; Tenney D; Spreng RL; Zhang L; Yates NL; Montefiori DC; Eller MA; Easterhoff D; Hope TJ; Rerks-Ngarm S; Pittisuttithum P; Nitayaphan S; Excler JL; Kim JH; Michael NL; Robb ML; O'Connell RJ; Karasavvas N; Vasan S; Ferrari G; Tomaras GD;
PLoS Pathog; 2023 May; 19(5):e1011359. PubMed ID: 37256916
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
12. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd
Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
[TBL] [Abstract][Full Text] [Related]
13. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
14. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
Karasavvas N; Billings E; Rao M; Williams C; Zolla-Pazner S; Bailer RT; Koup RA; Madnote S; Arworn D; Shen X; Tomaras GD; Currier JR; Jiang M; Magaret C; Andrews C; Gottardo R; Gilbert P; Cardozo TJ; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Paris R; Greene K; Gao H; Gurunathan S; Tartaglia J; Sinangil F; Korber BT; Montefiori DC; Mascola JR; Robb ML; Haynes BF; Ngauy V; Michael NL; Kim JH; de Souza MS;
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1444-57. PubMed ID: 23035746
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
[TBL] [Abstract][Full Text] [Related]
16. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
[TBL] [Abstract][Full Text] [Related]
17. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
Fouda GG; Cunningham CK; McFarland EJ; Borkowsky W; Muresan P; Pollara J; Song LY; Liebl BE; Whitaker K; Shen X; Vandergrift NA; Overman RG; Yates NL; Moody MA; Fry C; Kim JH; Michael NL; Robb M; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Liao HX; Haynes BF; Montefiori DC; Ferrari G; Tomaras GD; Permar SR
J Infect Dis; 2015 Feb; 211(4):508-17. PubMed ID: 25170104
[TBL] [Abstract][Full Text] [Related]
18. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
Easterhoff D; Pollara J; Luo K; Tolbert WD; Young B; Mielke D; Jha S; O'Connell RJ; Vasan S; Kim J; Michael NL; Excler JL; Robb ML; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Wiehe K; Saunders KO; Montefiori DC; Tomaras GD; Moody MA; Pazgier M; Haynes BF; Ferrari G
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776278
[TBL] [Abstract][Full Text] [Related]
19. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.
Rouphael NG; Morgan C; Li SS; Jensen R; Sanchez B; Karuna S; Swann E; Sobieszczyk ME; Frank I; Wilson GJ; Tieu HV; Maenza J; Norwood A; Kobie J; Sinangil F; Pantaleo G; Ding S; McElrath MJ; De Rosa SC; Montefiori DC; Ferrari G; Tomaras GD; Keefer MC;
J Clin Invest; 2019 Nov; 129(11):4769-4785. PubMed ID: 31566579
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Karnasuta C; Paris RM; Cox JH; Nitayaphan S; Pitisuttithum P; Thongcharoen P; Brown AE; Gurunathan S; Tartaglia J; Heyward WL; McNeil JG; Birx DL; de Souza MS;
Vaccine; 2005 Mar; 23(19):2522-9. PubMed ID: 15752839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
